Strategic Focus Interface Biologics specializes in anti-thrombogenic polymer technology for blood-contacting medical devices and polymer-enabled drug delivery systems, presenting opportunities to partner with device manufacturers seeking safer, more effective materials.

Acquisition Legacy Past asset sale to Evonik indicates a strategic shift or potential for licensing, partnership, or continued collaboration in surface modification technologies with larger players and contract manufacturers.

Private Funding With funding around thirty-two million and annual revenue under one million, there is room for targeted collaborations or pilot programs that minimize risk while validating their Endexo-like surface modifications in new device categories.

Growth Roles Key leadership addition in business development (2018) signals emphasis on market expansion, partnerships, and customer acquisition—ideal entry points for SVP/BD outreach and channel partnerships.

Market Readiness Commercial-stage biotech with a small team presents opportunities for co-development, faster decision cycles, and emphasis on early validation studies with medtech OEMs and pharmaceutical device collaborators.